10-hydroxyamitriptyline: metabolite of amitryptyline; RN given refers to parent cpd without isomeric designation
ID Source | ID |
---|---|
PubMed CID | 6454906 |
CHEMBL ID | 3544582 |
CHEBI ID | 174098 |
MeSH ID | M0104512 |
Synonym |
---|
CHEBI:174098 |
(2e)-2-[3-(dimethylamino)propylidene]tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,11,13-hexaen-9-ol |
64520-05-4 |
e-10-hydroxyamitriptyline |
SMP2_000003 |
10-hydroxyamitriptyline |
1159-82-6 |
5h-dibenzo(a,d)cyclohepten-10-ol, 5-(3-(dimethylamino)propylidene)-10,11-dihydro-, (e)- |
unii-8646k54i21 |
10-hydroxyamitriptyline, (e)- |
8646k54i21 , |
trans-10-hydroxyamitriptyline |
(e)-10-hydroxyamitriptyline |
10-hydroxyamitriptyline, (e)-(+/-)- |
5h-dibenzo(a,d)cyclohepten-10-ol, 5-(3-(dimethylamino)propylidene)-10,11-dihydro-, (5e)- |
CHEMBL3544582 |
(2e)-2-[3-(dimethylamino)propylidene]tricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3(8),4,6,12,14-hexaen-9-ol |
5-(3-(dimethylamino)propylidene)-10,11-dihydro-5h-dibenzo[a,d]cyclohepten-10-ol |
DTXSID50873786 |
Q27269700 |
(+/-)-e-5-[3-(dimethylamino)propylidene]-10.11-dihydro-5h-dibenzo[a,d]cyclohepten-10-ol |
amitriptyline metabolite (+/-)- |
5h-dibenzo[a,d]cyclohepten-10-ol, 5-[3-(dimethylamino)propylidene]-10,11-dihydro-, (5e)- |
(e)-5-(3-(dimethylamino)propylidene)-10,11-dihydro-5h-dibenzo[a,d][7]annulen-10-ol |
Class | Description |
---|---|
organic tricyclic compound | |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 4 (30.77) | 18.7374 |
1990's | 8 (61.54) | 18.2507 |
2000's | 1 (7.69) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 1 (7.14%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 13 (92.86%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |